Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Post-Mkt 02-03 17:11:51 EST

1.46

+0.02

+1.39%

盘后1.46

+0.000.00%

16:10 EST

High1.48	Low1.41	Vol208.43K
Open1.45	D1 Closing1.44	Amplitude4.86%
Mkt Cap185.42M	Tradable Cap100.42M	Total Shares127.00M
T/O299.76K	T/O Rate0.30%	Tradable Shares68.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":1.46,"timestamp":1770152400000,"preClose":1.44,"halted":0,"volume":208429,"hourTrading":{"tag":"盘后","latestPrice":1.46,"preClose":1.46,"latestTime":"16:10 EST","volume":110,"amount":160.6,"timestamp":1770153004708,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013888888888888902,"floatShares":68779500,"shares":127000000,"eps":-0.1143,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"02-03 17:11:51 EST","open":1.45,"high":1.48,"low":1.41,"amount":299756.0256,"amplitude":0.048611,"askPrice":1.76,"askSize":100,"bidPrice":1.37,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-0.1143,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770166800000},"marketStatusCode":4,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":1.44,"preHourTrading":{"tag":"盘前","latestPrice":1.56,"preClose":1.44,"latestTime":"09:27 EST","volume":643,"amount":920.5899801,"timestamp":1770128874407,"change":0.12,"changeRate":0.083333,"amplitude":0.111111},"postHourTrading":{"tag":"盘后","latestPrice":1.46,"preClose":1.46,"latestTime":"16:10 EST","volume":110,"amount":160.6,"timestamp":1770153004708,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.068328,"impliedVol":0.4363,"impliedVolPercentile":0.0518},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2605110865","title":"Tiziana Life Sciences announces publication of intranasal foralumab results","url":"https://stock-news.laohu8.com/highlight/detail?id=2605110865","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605110865?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:20","pubTimestamp":1768926010,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive mult...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-publication-of-intranasal-foralumab-results-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-publication-of-intranasal-foralumab-results-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2605117997","title":"Tiziana Life Sciences Publishes Positive Clinical Results for Intranasal Foralumab in Progressive MS","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117997","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605117997?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:15","pubTimestamp":1768925713,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced the peer-reviewed publication of clinical study results for its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in patients with non-active secondary progressive multiple sclerosis . The results were published in the journal Neurology Neuroimmunology & Neuroinflammation. The study showed clinical stabilization and biological effects of intranasal foralumab, including increased regulatory T cells and TGFβ expression. Tiziana is currently conducting an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS, with top-line data expected in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL4H50fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","TLSA","IE00B64PRP62.GBP","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2605117933","title":"Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605117933?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:15","pubTimestamp":1768925700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA8NXCQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2603998089","title":"Tiziana Life Sciences Launches Registered Direct Offering With Attached Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2603998089","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603998089?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:00","pubTimestamp":1768564814,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced a registered direct offering of 6,400,000 ordinary shares at $1.25 per share to senior management and existing shareholders. As part of the offering, for each ordinary share subscribed, participants will receive one warrant to purchase an additional ordinary share at a price of $1.50, exercisable until July 16, 2026. The warrants could result in additional gross proceeds of up to approximately $9.6 million if fully exercised. The offering aims to fund completion of the company’s Phase 2 na-SPMS and MSA clinical trials and achieve top line data readouts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via Gl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL7YVwlR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","TLSA","BK4585"],"gpt_icon":0},{"id":"2603799803","title":"Press Release: Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2603799803","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603799803?lang=en_us&edition=fundamental","pubTime":"2026-01-16 20:00","pubTimestamp":1768564800,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 16, 2026  -- Tiziana Life Sciences, Ltd.  , a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best efforts registered direct offering  of 6,400,000 ordinary shares at an Offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The total gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, are expected to be $8.0 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and including July 16, 2026  resulting in additional gross proceeds of up to approximately $9.6 million. The Offering is expected to close on January 16, 2026, subject to the satisfaction of customary closing conditions.This pres","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA","LU2247934214.USD","LU0823417653.USD","LU1430594728.SGD","LU1043141123.HKD","BK4585","LU0006061336.USD","BK4588","BK4577","LU0950375773.USD","LU2506952170.USD","LU0994945656.USD","BK4085","LU0823417737.USD","LU2506952097.USD","LU2506951875.HKD","BK4533","LU0426417589.USD","LU2506951958.HKD","LU0426412945.USD","LU1043141396.HKD","BK4532","LU1121112475.USD","LU1280957306.USD","EA","LU0640476718.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2602781403","title":"Tiziana Life Sciences to Present Intranasal Foralumab at Neuroscience Innovation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2602781403","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602781403?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960017,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. will present at the 9th Annual Neuroscience Innovation Forum on January 11, 2026, at the Marines' Memorial Club in San Francisco. Chief Executive Officer Ivor Elrifi is scheduled to deliver a corporate presentation highlighting the company's lead candidate, intranasal foralumab, an anti-CD3 monoclonal antibody targeting neurodegenerative conditions. Senior management will also attend the event for one-on-one meetings with investors, partners, and stakeholders. The forum is part of J.P. Morgan Healthcare Conference Week and focuses on advances in therapeutics, neurotechnology, and diagnostics for neurological disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the ori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1G5GQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0964807845.USD","IE00B1XK9C88.USD","LU2237443895.HKD","LU2264538146.SGD","LU0265550946.USD","IE0034235188.USD","LU0345769631.USD","IE00BZ1G4Q59.USD","IE00BKPKM429.USD","LU0323591593.USD","BK4581","LU2552382215.SGD","LU1496350502.SGD","LU2430703095.HKD","LU1894683348.USD","LU2237443382.USD","LU0943347566.SGD","LU2756315664.SGD","LU2095319765.USD","IE0034235303.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0211326839.USD","LU0310799852.SGD","BK4504","LU0971096721.USD","LU1551013425.SGD","LU2236285917.USD","BK4585","LU0942090050.USD","LU2023250330.USD","LU0320765646.SGD","LU1670628061.USD","LU2552382132.HKD","LU0106831901.USD","LU2756315318.SGD","TLSA","IE00BWXC8680.SGD","LU1496350171.SGD","IE00BKDWB100.SGD","LU1119994496.HKD","LU2746668974.SGD","IE00BBT3K403.USD","LU0208291251.USD","IE00BFXG1179.USD","IE00BN8TJ469.HKD","LU1162221912.USD","LU2211815571.USD","LU1116320737.USD"],"gpt_icon":0},{"id":"2592195055","title":"Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592195055","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592195055?lang=en_us&edition=fundamental","pubTime":"2025-12-20 00:00","pubTimestamp":1766160058,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has acquired 97,687 common shares of the company. Following this transaction, Mr. Cerrone's total holding amounts to 43,374,830 common shares, representing 36.08% of the issued share capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbmDv51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","TLSA","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2592911723","title":"Tiziana Life Sciences Publishes AGM Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911723","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911723?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:15","pubTimestamp":1765988123,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has published the presentation for its Annual General Meeting. The document includes proposals to be voted on at the meeting, details on proxy and poll voting results, and the outcomes for each resolution. The full presentation can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLKRV1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2592091977","title":"Tiziana Life Sciences Rings Nasdaq Closing Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091977?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:34","pubTimestamp":1765985667,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. marked a significant milestone by ringing the Closing Bell at the Nasdaq MarketSite in Times Square, New York. Executive Chairman and Founder, Gabriele Cerrone, led the ceremony, celebrating the company's recent achievements and ongoing advancements in innovative immunomodulation therapies. The event highlighted Tiziana's progress in developing its lead candidate, intranasal foralumab, and its commitment to addressing unmet medical needs in neurodegenerative and inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL4tgK5q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2592918073","title":"Tiziana Life Sciences Doses First Patient in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918073?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979118,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced the dosing of the first patient in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early Alzheimer's disease. The study will assess foralumab, a fully human anti-CD3 monoclonal antibody, as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab and donanemab. The trial is based on evidence of persistent neuroinflammation in Alzheimer's patients treated with anti-amyloid therapies. Results from the trial have not yet been presented and will be generated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL6VyPXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","SG9999014013.SGD","BK4585","BK4588","LU2210149790.SGD","NDAQ","TLSA","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2592091874","title":"Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091874?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUABFS1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2591621812","title":"Tiziana Life Sciences CEO Increases Stake With Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2591621812","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591621812?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:33","pubTimestamp":1765830800,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) said Monday its CEO, Ivor Elrifi, purchased 163,400 shares of common stock, bringing his total stake to 357,848 shares.Shares of the company were down over 17% in recent trading.Price: 1.47, Change: -0.31, Percent Change: -17.19","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591418629","title":"Tiziana Life Sciences CEO Purchases 163,400 Shares in Open Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2591418629","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591418629?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:08","pubTimestamp":1765829286,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his total purchased shares to 357,848.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2cgDpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","TLSA","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4139","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2591640488","title":"Tiziana Life Sciences Falls on Withdrawn Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640488","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591640488?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:33","pubTimestamp":1765812780,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences shares fell after the biotechnology company said it was withdrawing a proposed public stock offering.Shares were down 13% to $1.55 in Monday morning trading. The stock has more than doubled its value year-to-date.The Boston-based company had filed a prospectus with the Securities and Exchange Commission Friday outlining preliminary steps for a public offering of shares. It said Monday morning it was withdrawing the proposal due to market conditions.The Friday filing did not specify how many shares would be offered at what value. The company said it would have used proceeds from the filing to fund the development of intranasal foralumab, its leading drug candidate.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2591641253","title":"Tiziana Life Sciences Withdraws Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591641253?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:41","pubTimestamp":1765806088,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) said Monday it has withdrawn its proposed public offering of common shares, citing market conditions.Tiziana Life shares were 3.4% higher in premarket trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591646679","title":"BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646679?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:31","pubTimestamp":1765801912,"startTime":"0","endTime":"0","summary":"BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public OfferingDec 15 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:TIZIANA LIFE SCIENCES ANNOUNCES WITHDRAWAL OF PROPOSED PUBLIC OFFERINGSource text: ID:nGNXDhgvgFurther company coverage: TLSA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA1NSCHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2591689646","title":"Tiziana Life Sciences: Withdrawal of Proposed Public Offering of Common Shares Due to Market Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591689646?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:30","pubTimestamp":1765801807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XK052:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2591686571","title":"Tiziana Life Sciences Launches Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686571","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686571?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:10","pubTimestamp":1765566613,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced the initiation of patient enrollment in its Phase 2 randomized, placebo-controlled clinical trial investigating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in early Alzheimer's disease. The trial will evaluate foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab or donanemab. According to the company, the first patient is expected to be dosed next week. Baseline clinical assessments, cognitive testing, TSPO-PET imaging, and biomarker collection have been completed in initial participants. Results from the study have not yet been presented and will be available in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tizi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2rX3hG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","LU2210150020.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2591567686","title":"Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591567686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591567686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:10","pubTimestamp":1765566600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA1NWV6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2588030542","title":"Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030542","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030542?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676831,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced plans to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, and related assets into a separate publicly traded company. The move aims to enhance strategic focus and unlock value for shareholders, who will receive shares in the new entity via a distribution in specie. The spinout, which will center on the IL-6 market, is subject to shareholder approval and meeting listing requirements. The decision follows increased industry interest in IL-6 pathway therapeutics, highlighted by Novartis' recent $1.4 billion acquisition of Tourmaline Bio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7PC3yD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","IE00BGHQF748.EUR","TLSA","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","LU2210150020.SGD","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":-0.1},{"period":"3month","weight":-0.2},{"period":"6month","weight":-0.382},{"period":"1year","weight":1.1022},{"period":"ytd","weight":-0.0336}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.062066},{"month":2,"riseRate":0.125,"avgChangeRate":-0.00078},{"month":3,"riseRate":0.428571,"avgChangeRate":0.177199},{"month":4,"riseRate":0.571429,"avgChangeRate":0.151459},{"month":5,"riseRate":0.428571,"avgChangeRate":0.199364},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.000341},{"month":7,"riseRate":0.428571,"avgChangeRate":0.326851},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.143149},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.016089},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.076885},{"month":11,"riseRate":0,"avgChangeRate":-0.127748},{"month":12,"riseRate":0,"avgChangeRate":-0.132657}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}